Niacin/simvastatin compared to simvastatin alone at 2 doses
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Established Carotid Atherosclerosis
Conditions
Established Carotid Atherosclerosis
Trial Timeline
Jan 1, 2000 → Sep 1, 2005
NCT ID
NCT00307307About Niacin/simvastatin compared to simvastatin alone at 2 doses
Niacin/simvastatin compared to simvastatin alone at 2 doses is a approved stage product being developed by Merck for Established Carotid Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00307307. Target conditions include Established Carotid Atherosclerosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00307307 | Approved | Completed |
Competing Products
2 competing products in Established Carotid Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| NNC0385-0434 | Novo Nordisk | Phase 1 | 32 |